AMG 853 is an investigational small molecule developed for potential use in cancer immunotherapy. It functions as a dual inhibitor targeting both the PI3K and mTOR signaling pathways, which are frequently dysregulated in various cancers. By modulating these pathways, AMG 853 aims to suppress tumor growth and enhance anti-tumor immune responses. It has been studied in preclinical models for its ability to inhibit proliferation of cancer cells and modulate the tumor microenvironment, particularly by affecting immune cell activity such as T-cell function and myeloid-derived suppressor cells. Its application is primarily focused on solid tumors where PI3K/mTOR pathway activation contributes to disease progression. Research is ongoing to evaluate its efficacy and safety in clinical settings.